Haemonetics (HAE) AI Stock Analysis

• Market Cap: $3.64B
• Dividend Yield: N/A
• Average Volume (3M): 576.97K
• Price to Earnings (P/E): 17.0
• Beta (1Y): 0.89
• Revenue Growth: 3.95%
• EPS Growth: 44.09%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.10
• Shares Outstanding: 48,036,995
• 10 Day Avg. Volume: 544,046
• 30 Day Avg. Volume: 576,966
• PEG Ratio: 0.44
• Price to Book (P/B): 3.87
• Price to Sales (P/S): 2.34
• P/FCF Ratio: 22.33
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 5.48
• Enterprise Value/Ebitda: 14.65
• 1Y Price Target: $80.67
• Price Target Upside: 45.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 69 Neutral
• Price Target: $61.00 ▲(9.65% Upside)

Haemonetics' strong financial performance is the most significant factor, supported by robust revenue growth and improved profitability. However, technical indicators suggest bearish momentum, and valuation metrics indicate moderate attractiveness. The earnings call and corporate events provide additional positive context, though challenges remain.

Positive Factors

Market Outlook

The outlook for the plasma space remains solid with positive comments regarding demand for plasma-derived therapies from multiple plasma fractionators.

Product Innovation

Blood Management Technology showed impressive growth driven by new product launches and account openings.

Revenue Performance

The Plasma segment outperformed expectations, contributing to a revenue beat for Haemonetics.

Negative Factors

Competitive Pressures

Interventional Technology segment revenue was below expectations, with competitive pressures affecting growth prospects.

Leadership and Strategy

Increased competition for VASCADE has prompted leadership and sales force changes at HAE.

Revenue Guidance

Management provided FY26 revenue and EPS guidance that was below consensus at the midpoints.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation, headquartered in Braintree, Massachusetts, is a global healthcare company specializing in blood management solutions. The company operates across multiple sectors, including blood and plasma collection, hospital transfusion management, and hemostasis management. Haemonetics offers a range of products and services designed to improve patient care and reduce the cost of healthcare delivery. Its core offerings include automated blood collection devices, software solutions for blood centers, and products for blood component separation and storage.

How the Company Makes Money

Haemonetics makes money primarily through the sale of its medical devices and software solutions to blood banks, plasma collection centers, and hospitals. The company's revenue streams include the sale of automated blood collection systems, blood processing equipment, and related consumables that are essential for the operation of these devices. Additionally, Haemonetics generates income from software licensing and support services, which provide critical data management and operational efficiencies for its clients. Strategic partnerships and long-term contracts with healthcare providers and organizations further bolster the company's revenue as these collaborations often involve the integration of Haemonetics' technology into large-scale blood management operations.

Haemonetics Financial Statement Overview

Summary

Haemonetics exhibits strong financial performance with consistent revenue growth, improved profit margins, and a solid balance sheet. The company has reduced its debt significantly, enhancing its equity position, and shows effective cash generation. However, there is room for improvement in the equity ratio.

Income Statement

Haemonetics has demonstrated consistent revenue growth with a notable increase from $993 million in 2022 to $1.36 billion in 2025, reflecting a strong upward trend. The gross profit margin has improved to 55.04%, indicating efficient cost management. The net profit margin has also strengthened to 12.32%, showcasing enhanced profitability. Additionally, the EBIT and EBITDA margins have shown positive growth, contributing to overall financial health.

Balance Sheet

The company's debt-to-equity ratio has improved significantly with a reduction in total debt from $808 million in 2024 to $304 million in 2025, reflecting a stronger equity position. The equity ratio of 33.48% implies a stable financial structure, while the return on equity of 20.42% indicates effective utilization of equity capital. Overall, the balance sheet shows a solid financial position, though there remains room for improving the equity ratio further.

Cash Flow

Haemonetics has experienced positive free cash flow growth with an increase from $115 million in 2024 to $142 million in 2025. The operating cash flow to net income ratio stands at 1.08, indicating effective cash generation relative to profit. The free cash flow to net income ratio of 0.85 supports the company's ability to generate cash after capital expenditures. Overall, the cash flow statement reflects a healthy cash position and efficient cash management practices.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.36B	1.36B	1.31B	1.17B	993.20M	870.46M
Gross Profit	748.96M	748.96M	691.55M	615.10M	505.50M	397.84M
EBITDA	279.98M	337.40M	265.58M	249.34M	178.50M	142.25M
Net Income	167.68M	167.68M	117.56M	115.40M	43.38M	79.47M
Balance Sheet
Total Assets	2.45B	2.45B	2.20B	1.93B	1.86B	1.82B
Cash, Cash Equivalents and Short-Term Investments	306.76M	306.76M	178.80M	284.47M	259.50M	192.31M
Total Debt	1.22B	1.22B	807.79M	765.89M	773.59M	707.61M
Total Liabilities	1.63B	1.63B	1.24B	1.12B	1.11B	1.09B
Stockholders Equity	820.84M	820.84M	959.96M	818.00M	749.42M	731.67M
Cash Flow
Free Cash Flow	142.45M	142.45M	115.45M	162.87M	75.75M	71.77M
Operating Cash Flow	181.72M	181.72M	181.75M	273.06M	172.26M	108.81M
Investing Cash Flow	-161.90M	-161.90M	-322.39M	-143.79M	-86.34M	-425.44M
Financing Cash Flow	108.82M	108.82M	38.16M	-100.36M	-15.75M	367.45M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 55.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Negative. The current price of 55.63 is below the 20-day moving average (MA) of 73.89, below the 50-day MA of 72.90, and below the 200-day MA of 71.72, indicating a bearish trend. The MACD of -0.96 indicates Positive momentum. The RSI at 19.70 is Positive, neither overbought nor oversold. The STOCH value of 50.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDX	80 Outperform	$50.70B	33.76	6.26%	2.17%	5.84%	15.12%
HOLX	74 Outperform	$14.88B	28.18	11.38%	―	1.28%	-17.73%
ATR	71 Outperform	$9.13B	23.90	15.36%	1.28%	1.51%	21.70%
TFX	71 Outperform	$4.95B	26.38	4.36%	1.18%	1.11%	-23.73%
HAE	69 Neutral	$3.64B	16.98	18.27%	―	3.95%	44.09%
ICUI	65 Neutral	$3.12B	―	-4.62%	―	7.19%	-56.19%
Sector *	51 Neutral	$7.37B	0.24	-62.86%	2.36%	15.01%	-2.64%

Haemonetics Corporate Events

Haemonetics Holds Successful Annual Shareholders Meeting

On July 24, 2025, Haemonetics Corporation held its Annual Meeting of Shareholders, achieving a quorum with 94.95% of shares represented. During the meeting, shareholders elected nine directors for one-year terms, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending March 28, 2026.

The most recent analyst rating on (HAE) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.

Haemonetics Approves Strategic Alignment Initiative in May 2025

In May 2025, Haemonetics‘ Board of Directors approved a strategic market and regional alignment initiative aimed at enhancing operational performance and reducing costs. This initiative is expected to incur restructuring charges of approximately $20 million, with anticipated annual savings of $30 million upon completion by the end of fiscal 2027. The company reported strong financial results for fiscal 2025, with a 4% increase in annual revenue to $1.361 billion and significant improvements in earnings and cash flow. Despite a decline in fourth-quarter revenue, Haemonetics achieved record margin expansion and operating income growth, driven by its hospital business and strategic pricing initiatives.